Floatz logo

Horse Anti-Thymocyte Globulin

Beta Thalassemia

New York Medical CollegePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Beta Thalassemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Memorial Sloan Kettering Cancer Center
Phase 2BB
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2B
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B
Busulphan
New York Medical College
Phase 2B
Evomela
New York Medical College
Phase 2B

View all 19 →

Same molecule, other indications

Horse Anti-Thymocyte Globulin is also rated in:

bone marrow failure syndromeDormant
B
Indicative ·
62 / 100
View asset →
immunodeficiency diseaseDormant
B
Indicative ·
56 / 100
View asset →
Fanconi anemiaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →